共 25 条
- [1] Hortlund M(2017)Cancer risks after solid organ transplantation and after long-term dialysis Int J Cancer 140 1091-1101
- [2] Arroyo Muhr LS(2021)Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: a comprehensive review Cancer Sci 112 2607-2624
- [3] Storm H(2016)Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment Br J Clin Pharmacol 82 696-705
- [4] Yasuda H(2019)Successful employment of brentuximab vedotin in a patient undergoing hemodialysis: the first real-life experience Clin Lymphoma Myeloma Leuk 19 e595-e596
- [5] Yasuda M(2021)Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study Jpn J Clin Oncol 51 70-77
- [6] Komatsu N(2019)Pharmacokinetic and metabolism studies of monomethyl Auristatin F via liquid chromatography-quadrupole-time-of-flight mass spectrometry Molecules 24 2754-811
- [7] Zhao B(2021)Whole-body pharmacokinetics and physiologically based pharmacokinetic Model for Monomethyl Auristatin E (MMAE) J Clin Med 10 1332-undefined
- [8] Chen R(2022)Hodgkin lymphoma on hemodialysis: a review of treatment and recommendations Clin Lymphoma Myeloma Leuk 22 805-undefined
- [9] O'Connor OA(undefined)undefined undefined undefined undefined-undefined
- [10] Nanni L(undefined)undefined undefined undefined undefined-undefined